Dr. Schiller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UCLA Medical Center
10833 LeConte Ave, 42-121 CHS
Los Angeles, CA 90095Phone+1 310-825-5513Fax+1 310-825-2309- Is this information wrong?
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1984 - 1987
- Keck School of Medicine of the University of Southern CaliforniaClass of 1984
Certifications & Licensure
- CA State Medical License 1985 - 2025
- FL State Medical License 2015 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:LA Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2000 Sep 01
- Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2001 Sep 01
- An Open-Label, Phase II (Proof Of Concept) Trial Of PKC412 Monotherapy In Patients With Acute Myeloid Leukemia (AML) And Patients With High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m) acute myeloid leukemia (AML).Brian A Jonas, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Jorge Cortes, Gary Schiller, Alice Mims, Gail J Roboz, Jus...> ;Leukemia & Lymphoma. 2024 Mar 27
- Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.Joshua P Sasine, Natalia Y Kozlova, Lisa Valicente, Jennifer Dukov, Dana H Tran, Heather A Himburg, Sanjeev Kumar, Sarah Khorsandi, Aldi Chan, Samantha Grohe, Michelle...> ;Cancer Research. 2024 Mar 15
- Considerations regarding maintenance therapy for acute myeloid leukemia in remission.Kustanovich, V., Schiller, G.> ;Expert Review of Anticancer Therapy. 2024 Feb 12
- Join now to see all
Journal Articles
- Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AMLAlexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
Abstracts/Posters
- Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- The Scientific Sessions from ASH 2021December 2021
Press Mentions
- CIRM Grant Will Help Expand Patients’ Access to UCLA Clinical Trials for Stem Cell, Gene TherapiesOctober 27th, 2022
- African-American Blood Donors Needed to Help People with Sickle Cell DiseaseOctober 4th, 2022
- UCLA Jonsson Comprehensive Cancer Center Researchers at ASH 2021 Annual Meeting and ExpositionDecember 14th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Spanish, German, Hebrew
Hospital Affiliations
- Ronald Reagan UCLA Medical CenterLos Angeles, California
- UCLA Medical Center-Santa MonicaSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: